The National Pharmaceutical Council and the Personalized Medicine Coalition are co-hosting Comparative Effectiveness Research and Personalized Medicine: Policy, Science, and Business, a conference that will help better define the important interface of comparative effectiveness research and personalized medicine, and define pathways forward.
Comparative Effectiveness Research (CER) -- one of the most intensely debated topics in health care reform -- has emerged in parallel with personalized medicine -- one of the most exciting advances in medical science. This groundbreaking conference will bring together leaders from government, medicine, the patient community, industry, and academe to address these important topics. The conference will be directly relevant to ongoing policy debates about patient choice, cost containment, and medical science, and the discussion is well-timed as we continue to define how publicly funded CER will be implemented.
The $1.1 billion in new CER funding provided under the American Recovery and Reinvestment Act and ongoing discussion of the issue in health care reform have catalyzed an ongoing debate in which many stakeholders are intensely engaged. Questions to be answered include how the research will be conducted, who will guide the research, and how the results will drive patient focused clinical and policy decisions. The decisions made in coming months will affect medical decision-making, health care policy, and the direction and speed of scientific progress for years to come.
CER has traditionally used broad population averages as a means to compare and evaluate different treatments and health interventions. But as molecular science, health information technology, and novel epidemiologic methods mature and converge, it is vital that CER and the resulting policy incentives take full advantage of the emerging knowledge of the heterogeneity of patient response to treatment.
This conference will: